|
Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases Clinical research trials and Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases. Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases clinical trial. Human subjects often obtain the finest healthcare possible for their Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases  Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases
Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases
For Condition: bone metastases,recurrent prostate cancer
Status: No longer recruiting
Sponsor(s): EORTC Genito-Urinary Tract Cancer Cooperative Group ,
Synopsis: RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of strontium or radiation therapy in treating patients with prostate cancer that is refractory to hormone therapy who have painful bone metastases.
Details: OBJECTIVES: I. Compare, in a randomized Phase III setting, the subjective response rate, time to progression, and survival of patients with hormone-refractory prostate cancer with painful osseous metastases treated with either strontium-89 or palliative local radiotherapy. II. Compare the quality of life achieved on these two regimens. III. Determine the toxicity and morbidity of treatment on these two regimens. IV. Compare the cost effectiveness of these two regimens. PROTOCOL OUTLINE: Randomized study. Arm I: Radioisotope therapy. Strontium-89 chloride, Strontium-89. Arm II: Radiotherapy. Involved-field irradiation (equipment unspecified). PROJECTED ACCRUAL: 200 patients will be entered over 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically or cytologically proven carcinoma of the prostate that has relapsed subsequent to chemical or surgical castration and/or antiandrogen therapy - Painful, unirradiated osseous metastasis required; Documentation by bone scan and x-ray required - Number and extent of metastases determined according to Soloway and fitting grades 1-3 - Prior hormonal therapy must have lasted at least 3 months and must be continued until completion of this study - No imminent paraplegia related to metastases - No uncorrectable urinary incontinence --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No restriction - Endocrine therapy: Prior and concurrent hormonal therapy required - Radiotherapy: No prior strontium-89; No prior hemibody or total-body irradiation; Prior local-field irradiation for bone metastases allowed provided new site of painful metastases exists - Surgery: Surgical castration allowed --Patient Characteristics-- - Age: Any age - Performance status: WHO 0-2 - Hematopoietic: WBC greater than 3,500; Platelets greater than 150,000 - Hepatic: Not specified - Renal: Creatinine no greater than 2.2 mg/dl (200 micromoles/liter) - Other: No calcium supplementation; No second malignancy except basal cell skin cancer
Total Enrollment:
Location and Contact Information:
Overall Study Official:
G.O.N.Oosterhof, Study Chair, EORTC Genito-Urinary Tract Cancer Cooperative Group
Hospital Santa Maria
Lisbon, , 1699
Portugal
San Raffaele Hospital
Rome, , 00144
Italy
Universita Degli Studi di Firenze - Policlin. di Careggi
Florence, , 1 (50-134)
Italy
U.Z. Gasthuisberg
Leuven, , B-3000
Belgium
Inselspital, Bern
Bern, , CH-3010
Switzerland
Ospedale di Circolo e Fondazione Macchi
Varese, , 21100
Italy
Newcastle General Hospital
Newcastle upon Tyne, England, NE4 6BE
United Kingdom
Universitair Ziekenhuis Gent
Ghent, , B-9000
Belgium
Universitair Ziekenhuis Antwerpen
Edegem, , B-2650
Belgium
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
Warsaw, , 02-781
Poland
Medical Radiological Research Center
Obninsk, ,
Russian Federation
Academisch Medisch Centrum
Amsterdam, , 1105 AZ
Netherlands
Rigshospitalet
Copenhagen, , 2100
Denmark
Ospedale B. Ramazzini
Carpi, , 41012
Italy
Groot Ziekengasthuis 's-Hertogenbosch
's-Hertogenbosch, , 5211 NL
Netherlands
Academisch Ziekenhuis Groningen
Groningen, , 9713 EZ
Netherlands
Antoni van Leeuwenhoekhuis
Amsterdam, , 1066 CX
Netherlands
Cliniques Universitaires Saint-Luc
Brussels, , 1200
Belgium
Instituto Scientifico H.S. Raffaele
Milan, , 20132
Italy
University Medical Center Nijmegen
Nijmegen, , NL-6252 HB
Netherlands
Aarhus Kommunehospital
Aarhus, , DK-8000
Denmark
Additional Information:
Study ID Numbers: CDR0000077931; EORTC-30921
Study Start Date: October 1992
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002503
Other Recurrent Prostate Cancer Studies:
1. Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
2. Hormone Therapy With or Without Mitoxantrone and Prednisone in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
3. Chemotherapy in Treating Patients With Prostate Cancer
4. Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
5. Brachytherapy in Treating Patients With Recurrent Prostate Cancer
Related Studies:
Other recurrent prostate cancer Clinical Trials
Other Clinical Trials
Other Copenhagen Clinical Trials
Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases
|
|
|
|
|
|
|
|
